| Oscar Insurance Guidelines | Home Care - Skilled Nursing Care (RN, LVN/LPN) | 2025-09-01 |
| BCBS Texas Medical Policies | Chelation Therapy for Off-Label Uses | 2025-09-01 |
| BCBS Texas Medical Policies | Inhaled Nitric Oxide | 2025-09-01 |
| UHC Medicare Advantage | Skilled Nursing Facility, Rehabilitation, and Long-Term Acute Care Hospital – Medicare Advantage Medical Policy | 2025-09-01 |
| UHC UMR Medical and Drug | Reblozyl® (Luspatercept-Aamt) – Commercial Medical Benefit Drug Policy | 2025-09-01 |
| UHC UMR Medical and Drug | Susvimo® (Ranibizumab Injection) – Commercial Medical Benefit Drug Policy | 2025-09-01 |
| UHC UMR Medical and Drug | Vyepti® (Eptinezumab-Jjmr) – Commercial Medical Benefit Drug Policy | 2025-09-01 |
| UHC Surest Medical and Drug | Reblozyl® (Luspatercept-Aamt) – Commercial Medical Benefit Drug Policy | 2025-09-01 |
| UHC Surest Medical and Drug | Susvimo® (Ranibizumab Injection) – Commercial Medical Benefit Drug Policy | 2025-09-01 |
| UHC Surest Medical and Drug | Vyepti® (Eptinezumab-Jjmr) – Commercial Medical Benefit Drug Policy | 2025-09-01 |